Stock comparison
ResMed
Takeda Pharmaceutical Company Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
TAK
Takeda Pharmaceutical Company Limited
Market cap
$51.34B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TAK | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 44D | RMD |
| Benjamin Graham | 75B | 56C | RMD |
| Philip Fisher | 75B | 40D | RMD |
| Peter Lynch | 58C | 18F | RMD |
| Joel Greenblatt | 47D | 32F | RMD |
| Charlie Munger | 69B | 41D | RMD |
| Terry Smith | 73B | 36D | RMD |
Side-by-side metrics
| Metric | RMD | TAK |
|---|---|---|
| Market cap | $30.18B | $51.34B |
| P/E (TTM) | 19.6x | 43.0x |
| EV/EBIT | 17.1x | 22.0x |
| ROIC (TTM) | 19.63% | 2.59% |
| Gross margin | 61.69% | 58.76% |
| Net margin | 27.44% | 4.26% |
| Revenue CAGR 5y | 12.64% | 7.56% |
| EPS CAGR 5y | 30.73% | -3.46% |
| Debt / Equity | 0.1x | 0.6x |
| Dividend yield | 1.14% | 3.79% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- EPS CAGR 5y30.73%vs -3.46%+111%
- ROIC (TTM)19.63%vs 2.59%+87%
- Net margin27.44%vs 4.26%+84%
- Debt / Equity0.1xvs 0.6x+79%
TAK leads on
- Dividend yield3.79%vs 1.14%+70%
- Market cap$51.34Bvs $30.18B+41%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.